Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-4 in Chinese Patients With Postherpetic Neuralgia
NCT07275762Phase 2Recruiting
- Sponsor
- NeuroDawn
- Start
- Feb 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Y-4 in postherpetic neuralgia (PHN) (2 arms), sponsored by NeuroDawn. Primary endpoint: Change from baseline in Average Daily Pain Score at 13 weeks. Started Feb 2026; status: recruiting.
02
Drugs
Y-4
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT07275762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275762.